Abnormal factor IX variant proteins were isolated from the plasmas of three unrelated severe hemophilia-B families that had been previously shown to contain functionally impaired molecules immunologically similar to normal factor IX. The families studied were: (1) a patient with markedly prolonged ox brain prothrombin time, designated factor IX Bm Lake Elsinore (IXBmLE); (b) three patients (brothers) with moderately prolonged ox brain prothrombin time, designated factor IX Long Beach (IXLB); and (c) a patient with normal ox brain prothrombin time designated factor IX Los Angeles (IXLA). Each variant molecule comigrates with normal factor IX (IXN) both in the sodium dodecyl sulfate and in the nondenaturing alkaline gel electrophoresis. All three variant proteins are indistinguishable from IXN in their amino acid compositions, isoelectric points, carbohydrate distributions and number of gamma-carboxyglutamic acid residues. Each variant protein undergoes a similar pattern of cleavage by factor XIa/Ca2+ and by factor VIIa/Ca2+/tissue factor, and is activated at a rate similar to that observed for IXN. All of the three variant proteins also react with an anti-IXN monoclonal antibody that interferes with the binding of activated IXN(IXaN) to thrombin-treated factor VIIIC. However, in contrast to IXaN, the cleaved IXBmLE has negligible activity (approximately 0.2%), and cleaved forms of IXLA and IXLB have significantly reduced activity (approximately 5-6%) in binding to antithrombin-III/heparin, and in activating factor VII (plus Ca2+ and phospholipid) or factor X (plus Ca2+ and phospholipid) +/- factor VIII. These data, taken together, strongly indicate that the defect in these three variant proteins resides near or within the latent catalytic site. This results in virtually a complete loss of catalytic activity of the cleaved IXBmLE molecule and approximately 95% loss of catalytic activity of the cleaved IXLA and IXLB molecules.
P Usharani, B J Warn-Cramer, C K Kasper, S P Bajaj
Title and authors | Publication | Year |
---|---|---|
The Molecular Basis of FIX Deficiency in Hemophilia B.
Shen G, Gao M, Cao Q, Li W |
International journal of molecular sciences | 2022 |
F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes
A Branchini, M Morfini, B Lunghi, D Belvini, P Radossi, L Bury, ML Serino, P Giordano, D Cultrera, AC Molinari, M Napolitano, E Bigagli, G Castaman, M Pinotti, F Bernardi, P Agostini, C Biasioli, TM Caimi, F Daniele, A Dragani, D Gemmati, P Gresele, S Linari, G Rossetti, C Santoro, R Santoro, G Sottilotta, J Svahn |
Journal of Thrombosis and Haemostasis | 2021 |
F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes.
Branchini A, Morfini M, Lunghi B, Belvini D, Radossi P, Bury L, Serino ML, Giordano P, Cultrera D, Molinari AC, Napolitano M, Bigagli E, Castaman G, Pinotti M, Bernardi F |
Journal of Thrombosis and Haemostasis | 2021 |
Methods in Enzymology
JD Stone, AS Chervin, DH Aggen, DM Kranz |
Protein Engineering for Therapeutics Part B | 2012 |
Vitamins & Hormones
KJ Hare, FK Knop |
Vitamins & Hormones | 2010 |
Detailed characterization of an anti-factor IX monoclonal antibody that neutralizes the prolonged ox brain prothrombin time of hemophilia BM by synthetic peptides
I Takahashi, T Kojima, M Sano, T Watanabe, T Kamiya, H Saito |
Peptides | 2000 |
Protease and EGF1 Domains of Factor IXa Play Distinct Roles in Binding to Factor VIIIa: IMPORTANCE OF HELIX 330 (HELIX 162 IN CHYMOTRYPSIN) OF PROTEASE DOMAIN OF FACTOR IXa IN ITS INTERACTION WITH FACTOR VIIIa
A Mathur, SP Bajaj |
The Journal of biological chemistry | 1999 |
Anticoagulant repertoire of the hookworm Ancylostoma caninum
P Stassens, PW Bergum, Y Gansemans, L Jespers, Y Laroche, S Huang, S Maki, J Messens, M Lauwereys, M Cappello, PJ Hotez, I Lasters, GP Vlasuk |
Proceedings of the National Academy of Sciences | 1996 |
Evidence Suggestive of Activation of the Intrinsic Pathway of Blood Coagulation After Injection of Factor Xa/Phospholipid Into Rabbits
BJ Warn-Cramer, SI Rapaport |
Arteriosclerosis, thrombosis, and vascular biology | 1995 |
Prothrombin time using thromboplastins of different origin in hemophilia BM patients
A Girolami, E Zanon, P Radossi, S Gavasso |
American Journal of Hematology | 1994 |
Comparison of the behavior of normal factor IX and the factor IX BM variant hilo in the prothrombin time test using tissue factors from bovine, human, and rabbit sources
JB Lefkowitz, DM Monroe, CK Kasper, HR Roberts |
American Journal of Hematology | 1993 |
Mutations in the catalytic domain of factor IX that are related to the subclass hemophilia Bm
N Hamaguchi, H Roberts, DW Stafford |
Biochemistry | 1993 |
Identification of a new haemophilia BMcase produced by a mutation located at the carboxy terminal cleavage site of activation peptide
J Solera, M Magallón, J Martin-Villar, A Coloma |
British Journal of Haematology | 1991 |
A sulfated rabbit endothelial cell glycoprotein that inhibits factor VIIa/tissue factor is functionally and immunologically identical to rabbit extrinsic pathway inhibitor (EPI)
BJ Warn-Cramer, SL Maki, SI Rapaport |
Thrombosis Research | 1991 |
Replacement of isoleucine-397 by threonine in the clotting proteinase factor IXa (Los Angeles and Long Beach variants) affects macromolecular catalysis but not L-tosylarginine methyl ester hydrolysis. Lack of correlation between the ox brain prothrombin time and the mutation site in the variant proteins
SG Spitzer, BJ Warn-Cramer, CK Kasper, SP Bajaj |
Biochemical Journal | 1990 |
Experimental and theoretical evidence supporting the role of Gly363 in blood coagulation factor IXa (Gly193 in chymotrypsin) for proper activation of the proenzyme
SP Bajaj, SG Spitzer, WJ Welsh, BJ Warn-Cramer, CK Kasper, JJ Birktoft |
The Journal of biological chemistry | 1990 |
Defective propeptide processing and abnormal activation underlie the molecular pathology of factor IX Troed-y-Rhiw
MB Liddell, DP Lillicrap, IR Peake, AL Bloom |
British Journal of Haematology | 1989 |
Blood clotting factor IX BM Nagoya
K Suehiro, S Kawabata, T Miyata, H Takeya, J Takamatsu, K Ogata, T Kamiya, H Saito, Y Niho, S Iwanaga |
The Journal of biological chemistry | 1989 |
Molecular defect in factor IXBm Lake Elsinore. Substitution of Ala390 by Val in the catalytic domain
SG Spitzer, UR Pendurthi, CK Kasper, SP Bajaj |
The Journal of biological chemistry | 1988 |
Partial purification and characterization of extrinsic pathway inhibitor (the factor xa-dependent plasma inhibitor of factor VIIa/tissue factor)
BJ Warn-Cramei, SL Maki, A Zivelin, SI Rapaport |
Thrombosis Research | 1987 |
Intrinsic versus extrinsic coagulation. Kinetic considerations
BJ Warn-Cramer, SP Bajaj |
Biochemical Journal | 1986 |
Heterogeneity of factor IX BM difference of cleavage sites by factor XIa and Ca2+in factor IX Kashihara, Factor IX Nagoya and Factor IX Niigata
A Yoshioka, Y Ohkubo, T Nishimura, I Tanaka, H FuKui, K Ogata, T Kamiya, H Takahashi |
Thrombosis Research | 1986 |
The characterization of a panel of monoclonal antibodies to human coagulation factor IX
H Bessos, LR Micklem, M McCann, K James, D Brian, L McClelland, CV Prowse |
Thrombosis Research | 1985 |
Structure and Function of Factor IX: Defects in Haemophilia B
RA Mccgraw, LM Davis, RL Lundblad, DW Stafford, HR Roberts |
Clinics in Haematology | 1985 |